Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making
‘The NHS Is Under Capacity Pressure, We’re Asking For Change,’ Firm Says
Executive Summary
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.
You may also be interested in...
UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme
By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local R&D-based industry association, the ABPI.
UK Generics Body Opens Rift With Government And Originators Over Rebate Scheme
By launching a bid for judicial review of its exclusion from UK negotiations over the VPAS rebate scheme, the BGMA has thrust itself into conflict with the country’s government as well as local brand industry association the ABPI.
Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK
April brings news of further biosimilar competition to Lucentis in major European markets.